|Mr. Paul Edward-Alexander Hopper A.S.i.A, B.A (UNSW), FAICD||Executive Chairman||316.1k||N/A||1956|
|Ms. Leslie Chong||CEO, MD & Executive Director||1.05M||N/A||N/A|
|Mr. Michael Tonroe ACA, B.Sc., Bsc(Hons), F.C.A., M.A.I.C.D., MAICD||CFO & Company Secretary||424.28k||N/A||1966|
|Dr. Nicholas J. Ede B.Sc.(Hons.), Ph.D.||Head of Corporate Development||489.47k||N/A||N/A|
|Dr. Monil Shah M.B.A., Pharm.D.||Chief Business Officer||799.2k||N/A||N/A|
|Dr. Bradley Glover Ph.D.||Chief Operating Officer||N/A||N/A||1969|
|Ms. Ursula McCurry||Senior Vice President of Clinical Operations||N/A||N/A||N/A|
|Dr. John Byon||Senior Vice President of Clinical Development||N/A||N/A||N/A|
|Dr. Joseph Paul Woodard Jr., M.D.||Chief Medical Officer||N/A||N/A||N/A|
Imugene Limited, a clinical stage immuno-oncology company, develops a range of immunotherapies to activate the immune system of cancer patients to treat and eradicate tumors in Australia. Its lead product is HER-Vaxx, a HER2-positive cancer vaccine that stimulates a polyclonal antibody response against HER2/neu receptors in gastric and breast cancer. The company's HER-Vaxx is in phase 2 study for gastric cancer. It also engages in developing PD1-Vaxx, a cancer vaccine that aims to induce the body to produce polyclonal antibodies that block PD-1 signalling and is in phase I trial; and CF33, a combination of genomic sequences from various vaccinia virus strains to generate potent virus. The company has a collaboration with Arovella Therapeutics Ltd to test the integration of Arovella's CAR19- iNKT cell therapy with the onCARlytics platform, as well as a research collaboration with RenovoRx, Inc. to deliver oncolytic virus therapy for the treatment of difficult-to-access tumors. Imugene Limited was incorporated in 1986 and is based in Sydney, Australia.
Imugene Limited’s ISS governance QualityScore as of 1 December 2023 is 10. The pillar scores are Audit: 9; Board: 8; Shareholder rights: 1; Compensation: 10.